Drug combination shows effectiveness in patients with recurrent ER-positive endometrial cancer

A combination therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in 75% of patients with recurrent or persistent estrogen receptor- (ER-) positive endometrial cancer, results from a recent clinical trial show. Trial leaders from Dana-Farber Cancer Institute will present the findings at today's session of the Society of Gynecologic Oncology (SGO) Annual Meeting.

source https://medicalxpress.com/news/2022-03-drug-combination-effectiveness-patients-recurrent.html